Adeno-associated Virus (AAV) Vector-based Gene Therapy Market
Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Global Industry Assessment & Forecast
#
Pages:
220
2024
Nov - 2024
VMR-3397
Segments Covered
By
Disease Type Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology
-
By
Vector Serotype AAV1, AAV2, AAV5, AAV6, AAV8, AAV9
-
By
Administration Route Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral
-
By
End User Hospitals, Research Institutes, Biopharmaceutical Companies
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2034 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 6.02 Billion |
 Revenue 2034:
|
USD 32.96 Billion |
 Revenue CAGR
(2025 - 2034): |
18.2% |
Fastest Growing Region (2025 -
2034)
|
North America |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2019 to 2023 |
| 3. | Forecast Data | 2025 to 2034 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
FAQ
Frequently Asked Question
What is the global demand for Adeno-associated Virus (AAV) Vector-based Gene Therapy in terms of revenue?
-
The global Adeno-associated Virus (AAV) Vector-based Gene Therapy valued at USD 6.02 Billion in 2024 and is expected to reach USD 32.96 Billion in 2034 growing at a CAGR of 18.2%.
Which are the prominent players in the market?
-
The prominent players in the market are Pfizer, BioMarin Pharmaceutical, Sarepta Therapeutics, Takeda, UniQure, Regenxbio, Adverum Biotechnologies, Spark Therapeutics (Roche), Astellas Pharma, Bayer, Ultragenyx Pharmaceutical, Audentes Therapeutics (Astellas), Homology Medicines, GenSight Biologics, Sangamo Therapeutics..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 18.2% between 2025 and 2034.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Adeno-associated Virus (AAV) Vector-based Gene Therapy include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Adeno-associated Virus (AAV) Vector-based Gene Therapy in 2024.
